Active Ingredient(s): Inebilizumab-cdon
FDA Approved: * June 11, 2020
Pharm Company: * VIELA BIO
Category: Vision / Eye Health

Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults.[2][3][1] The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain.[2][1] Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells.[1] T... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Uplizna 10 mg/ml Intravenous Injection
NDC: 72677-551
Viela Bio, Inc.
Uplizna 10 mg/ml Intravenous Injection
NDC: 75987-150
Horizon Therapeutics USA, Inc.